Kenko Imalytics

We were born in 2021 as a company. Ten years ago, in spirit, we had a vision to fight against cancer. With the main objective of improving the early diagnosis of cancer, KENKO Imalytics is dedicated to the development of automatic software for the calculation of biomarkers from MRI images, focusing on prostate and breast cancer. Our focus is to improve the workflow of radiology, to be a useful tech tool for the professionals of diagnosis or the development of pioneering technologies through research to improve the quality of human life. Among others our Saas software provides: • Parametric maps of biomarkers • Combination of them in a single cancer probability image. Virtual biopsy is capable of predicting cancer in early stages and providing the results in a clear and easy to interpret way. In addition, the use of our software has the following advantages over standard clinical practice: - Reduced reporting time. - Better adaptability to MRI equipment - Reduction of the rate of false positives and negatives in breast and prostate cancer. With the immeasurable advantages that artificial intelligence offers us, we accompany and improve the experience of radiologists, oncologists, pathologists, researchers and institutions in their exciting daily work.